According to details of a Pfizer study posted online Friday, child-sized doses of the Pfizer COVID-19 vaccine were shown to be over 90% effective in preventing symptomatic COVID-19 infections in kids 5-11 years old. The details were published in a briefing document ahead of next week’s meeting of an advisory panel to the Food and Drug Administration. The video above shows an infectious disease specialist discuss the data.
The Pfizer study tracked 2,268 children in the 5-to-11 group who got two shots of either a placebo or the vaccine three weeks apart. There were 16 cases among the group of kids who got the placebo, compared to just three among people who got the vaccine. The Food and Drug Administration was expected to post its own review of the company’s safety and effectiveness data later in the day Friday.
Pfizer has already sought approval for use of its vaccine in kids age 5-11, and the Biden administration has already begun coming up with a plan for how to get vaccines to all 28 million Americans in that age group as quickly as possible. If regulators give their approval, 5-to-11-year-old Americans could start getting the vaccine in early November and be fully vaccinated by Christmas.
The news comes as the definition of “fully vaccinated” itself may change. Centers for Disease Control and Prevention Director Dr. Rochelle Walensky discussed the possibility a day after she had final approval allowing millions of more Americans to get booster shots. The video above also shows some of her comments.
“Right now, we don’t have booster eligibility for all people, currently, so we are going to we have not yet changed the definition of fully vaccinated,” Dr. Walensky said at Friday’s White House COVID-19 Response Team briefing. “We will continue to look at this. We may need to update our definition of fully vaccinated in the future.”
Right now, booster shots are only available for the following:
- All adults who got the Johnson & Johnson vaccine
- All seniors who got the Pfizer or Moderna vaccine, as well as the following:
- Adults who live in long-term care settings
- Adults who have underlying medical conditions
- Adults who work or live in high-risk settings